FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,286,567 | -76.3% | 1,002,002 | -47.0% | 0.03% | -75.8% |
| Q1 2024 | $13,887,295 | +863.6% | 1,892,002 | +391.0% | 0.13% | +700.0% |
| Q4 2023 | $1,441,261 | +202.6% | 385,364 | +285.1% | 0.02% | +166.7% |
| Q2 2023 | $476,267 | -16.4% | 100,056 | +0.1% | 0.01% | -25.0% |
| Q1 2023 | $570,023 | -64.8% | 100,004 | -37.8% | 0.01% | -63.6% |
| Q4 2022 | $1,621,645 | -55.0% | 160,718 | 0.0% | 0.02% | -56.0% |
| Q3 2022 | $3,602,000 | -9.6% | 160,718 | 0.0% | 0.05% | -18.0% |
| Q2 2022 | $3,983,000 | -36.1% | 160,718 | 0.0% | 0.06% | -39.6% |
| Q1 2022 | $6,231,000 | -46.5% | 160,718 | -19.3% | 0.10% | -39.5% |
| Q4 2021 | $11,648,000 | +28.5% | 199,076 | +30.2% | 0.17% | +12.8% |
| Q3 2021 | $9,066,000 | -20.3% | 152,957 | +16.7% | 0.15% | -30.2% |
| Q2 2021 | $11,379,000 | +9.2% | 131,106 | +3.8% | 0.21% | -8.2% |
| Q1 2021 | $10,418,000 | – | 126,360 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 2,473,186 | $24,138,000 | 13.76% |
| Casdin Capital, LLC | 2,600,000 | $25,376,000 | 4.46% |
| Redmile Group, LLC | 6,655,962 | $64,962,000 | 2.51% |
| 683 Capital Management, LLC | 993,711 | $9,699,000 | 0.86% |
| Endurant Capital Management LP | 155,344 | $1,516,000 | 0.57% |
| EAM Investors, LLC | 279,161 | $2,725,000 | 0.45% |
| EAM Global Investors LLC | 77,889 | $760,000 | 0.39% |
| PURA VIDA INVESTMENTS, LLC | 59,600 | $582,000 | 0.34% |
| Telemetry Investments, L.L.C. | 70,200 | $685,000 | 0.26% |
| DOHENY ASSET MANAGEMENT /CA | 29,490 | $288,000 | 0.15% |